Par Pharmaceutical starts shipment of generic version of Sodium Edecrin

Download PDF Copy

Aug 4 2015

NewsGuard 100/100 Score

Par Pharmaceutical today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for ethacrynate sodium for injection USP, equivalent to ethacrynic acid 50 mg. Ethacrynate sodium is the generic version of Aton Pharma's Sodium Edecrin^® and is used in the treatment of edema. Par's ethacrynate sodium for injection USP, 50 mg is the first and only generic available.

Par has begun shipping ethacrynate sodium for injection USP, which is packaged in cartons of one 50 mg single-dose vial. According to IMS Health data, annual U.S. sales of Sodium Edecrin^® are approximately $40 million.

Source:

Par Pharmaceutical

Posted in: Medical Condition News | Pharmaceutical News

Tags: Diarrhea, Drugs, Edema, Electrolyte, Food, New Drug Application, Pharmaceuticals

Comments (0)

Download PDF Copy

Suggested Reading

Obesity crisis in the U.S. expected to worsen by 2050

Obesity crisis in the U.S. expected to worsen by 2050

Tiny molecule offers hope in reducing opioid side effects

Tiny molecule offers hope in reducing opioid side effects

Antibiotic resistance threatens millions of lives worldwide

Antibiotic resistance threatens millions of lives worldwide

Early RSV vaccination in pregnancy provides best protection for newborns

Early RSV vaccination in pregnancy provides best protection for newborns

Study shows how a single defective BRCA1 gene accelerates cancer development

Study shows how a single defective BRCA1 gene accelerates cancer development

Study focuses on COPD progression in younger populations

Study focuses on COPD progression in younger populations

Urine RNA analysis shows promise for detecting genitourinary diseases

Urine RNA analysis shows promise for detecting genitourinary diseases

Tertiary lymphoid structures linked to improved outcomes in liver cancer patients

Tertiary lymphoid structures linked to improved outcomes in liver cancer patients

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Rising asthma rates in sub-Saharan Africa linked to urbanization and lack of care